Professional Cosmetics Peptide Supplier | GENOPEP
Acetyl Decapeptide-3 (CAS：935288‑50‑9) Anti-pigmentation Peptide
PRODUCT PARAMETERS
Description
Acetyl Decapeptide-3 Basic Information
| Field Name | Basic information |
| INCI Name | Acetyl Decapeptide-3 |
| CAS No. | 935288-50-9 |
| Synonyms | CG‑Rejulin, Rejuline, Rejulin, SpecPed® AD3P, Ac‑YRSRKYTSWY‑NH₂, Ac‑Tyr‑Arg‑Ser‑Arg‑Lys‑Tyr‑Thr‑Ser‑Trp‑Tyr‑NH₂ |
| Key Benefit | Anti-pigmentation/Anti-Winkle/Anti-Aging/Barrier Repair/Soothing and Anti-Inflammatory/Sensitive Skin Care/ Brightening |
Acetyl Decapeptide-3 Powder Specification
| Field Name | Basic information |
| Form | Powder |
| Appearance | White to off-white powder |
| Purity (HPLC) | ≥ 95% or ≥ 98% |
| Storage Conditions | Store sealed, protected from light and moisture. Long-term storage at -20°C is recommended. |
| Packaging | Glass/plastic sample bottles,or customized packages based on special requests. |
| Shipping | Express air freight with moisture-proof protection. |
| Inquiry | Request a Quote / Order Samples |
Acetyl Decapeptide-3 Solution Specification
| Item | Specification Details |
| Form | Liquid |
| Appearance | Clear Transparent Liquid |
| Peptide Content | 1000ppm (Customizable upon request) |
| Storage Conditions | Can transport at room temperature. Store in a dry, dark place at 2-8°C for long term storage. |
| Packaging | 1Kg or 5kg, or customized packages based on special requests. |
| Shipping | Express air freight with moisture-proof protection. |
| Sample | Request a Quote / Order Samples |
Acetyl Decapeptide-3 (CAS 935288-50-9): bFGF‑mimetic peptide. Boosts collagen (+38%), inhibits AGEs, reduces wrinkles 26%, repairs barrier. Anti‑inflammatory.
Advantage and Benefit
| Feature | Details |
| bFGF Mimicry & ECM Remodeling | Mimics basic fibroblast growth factor to activate FGFRs, stimulating collagen (I/III/IV), elastin, fibronectin, laminin, and GAGs while inhibiting MMPs to protect ECM integrity. |
| Anti‑Glycation & LOXL Activation | Activates lysyl oxidase (LOXL) by +150% to break down AGEs cross‑links, reversing collagen stiffening and skin yellowing; upregulates TGF‑β1 to boost type I/IV collagen (+38%). |
| Anti‑Inflammatory & Barrier Repair | Suppresses NF‑κB to reduce IL‑6/TNF‑α by 55%; upregulates filaggrin to lower TEWL by 18%, aligning with Shiseido’s barrier homeostasis research. |
| Clinically Proven Multi‑Benefit | Reduces nasolabial fold depth 26%, periorbital wrinkles 18.7%, increases elasticity 32%, reduces AGEs deposition 29%, and improves ITA° by 21% (8 weeks). |
FAQs
Q1. How does Acetyl Decapeptide-3 simultaneously address ECM remodeling, anti‑glycation, and antioxidant protection?
A: Acetyl Decapeptide-3 stimulates synthesis of collagen (I, III, IV), elastin, fibronectin, laminin, and GAGs while activating LOXL (+150%) to break down AGEs cross‑links, restoring collagen elasticity. It also inhibits MMPs to protect newly formed ECM, and via Nrf2 pathway activation, scavenges ROS (≥89% clearance), reducing oxidative damage. Clinical: 29% reduction in AGEs deposition, 21% increase in ITA° (8 weeks).
Q2. How does Acetyl Decapeptide-3 compare to native bFGF in terms of stability, safety, and efficacy for cosmetic applications?
A: Native bFGF is a large protein with poor skin penetration and rapid enzymatic degradation. Acetyl Decapeptide-3 is a smaller, acetylated synthetic peptide that repeats bFGF‘s functional sequence, offering superior stability and prolonged action in clinical tests. It retains receptor‑binding specificity without uncontrolled pleiotropic effects of the full protein, and is non‑irritating and vegan. It is an ideal biomimetic alternative for topical anti‑aging formulations.
Q3. How does Acetyl Decapeptide-3 achieve its anti-pigmentation effects on facial skin?
A: Acetyl Decapeptide-3 targets skin yellowing by activating lysyl oxidase (LOXL) to break down advanced glycation end-products (AGEs). AGEs accumulation leads to protein crosslinking and dermal yellowing—a key contributor to uneven pigmentation. Clinical data shows that 0.0001% of the peptide used for 8 weeks reduced AGEs deposition by 29% and improved skin yellowness index (ITA°) by 21% (Clinical, Cosmetic and Investigational Dermatology, 2023). By reversing glycation-induced discoloration, it restores a more even, luminous complexion.
GENOPEP GROUP | The Engine of Your Peptide Innovation
GENOPEP Group is a leading global peptide technology solutions provider, specializing in R&D, manufacturing, and commercialization in the fields of skin science and biopharmaceuticals. Supported by advanced scientific capabilities and a fully integrated supply chain, we deliver efficient and reliable innovation support to skincare brands worldwide.
We focus on three key service areas, empowering partners throughout the entire product lifecycle from concept to market:
- Active Ingredients and Formulation Development – Grounded in cutting-edge research, we provide high-efficacy skincare ingredients, ingredient complexes, and complete formulation solutions.
- End-to-End Production Support – Covering the full journey from lab-scale R&D and pilot optimization to commercial manufacturing, ensuring consistent product quality and reliable supply.
- Custom Synthesis Services – With strong capabilities in novel molecule development, we specialize in the design, synthesis, and preparation of peptide-based novel ingredients and related reference standards.
We believe in technology-driven products and collaboration-driven value. GENOPEP is not just a supplier—we are your trusted innovation partner, dedicated to co-creating the next generation of skincare solutions with you.
